

TITLE PAGE

Executive Functioning and Processing Speed as Predictors of Global Cognitive Decline in Alzheimer Disease

Authors:

John P. Haran^{1,2,3}, A M Barrett⁴, YuShuan Lai, MD, PhD^{2,3}, Samuel N. Odjidja¹, Protiva Dutta¹, Patrick M McGrath¹, Imane Samari¹, Lethycia Romeiro¹, Abigail Lopes¹, Vanni Bucci^{2,3}, and Beth A. McCormick^{2,3}

Affiliations:

¹Department of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655

²Department of Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655

³Program in Microbiome Research, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655

⁴Department of Neurology, UMass Chan Medical School and UMass Memorial Healthcare, Worcester, Massachusetts.

Corresponding Author: John P. Haran, MD, Ph.D., 55 Lake Avenue North, Worcester, MA 01655; Phone: 508-450-8688; email: john.haran@umassmed.edu; fax: 508-421-1490

2 **ABSTRACT**

3 **INTRODUCTION:** There is a lack of cognitive tools to predict disease progression in mild
4 cognitive impairment (MCI) and Alzheimer’s disease (AD).

5
6 **METHODS:** We assessed patients with MCI, AD, and cognitively healthy controls (cHC) using
7 NIH toolbox assessments for attention/concentration and executive functioning and overall
8 cognitive decline by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog).

9
10 **RESULTS:** Among 183 participants over a median follow-up of 540 days, both between- and
11 within-subjects variance in NIH toolbox and ADAS-Cog assessments increased from cHC to
12 MCI to AD patients. Among patients with AD, pattern comparison processing speed (PCPS) and
13 dimensional change card sort tests (DCCS) declined at 3 and 6 months prior to global cognitive
14 decline ($p=0.008$ & 0.0012). A 5-point decrease in either PCPS or DCCS increased risk of global
15 cognitive decline (HR 1.32 (1.08-1.60) and 1.62 (1.16-2.26)).

16
17 **DISCUSSION:** Testing for cognitive domains of attention/concentration and executive
18 functioning may predict subsequent global cognitive, and functional decline.

19
20 **Keywords:** Alzheimer’s disease, mild cognitive impairment, cognitive testing, NIH toolbox,
21 ADAS-Cog

22

23

24

25 INTRODUCTION

26 Today there are nearly 6.9 million older Americans living with Alzheimer’s disease (AD) (1).
27 AD is a progressive neurodegenerative disorder, however, there is much variability in the
28 observed rates of cognitive decline across the spectrum of AD (2-4). The average duration of the
29 disease varies between 4 and 8 years, with some upwards of 20 years (5). There are known
30 demographic and clinical characteristics as well as radiological and genetic features that
31 associate with the rate of cognitive decline (6, 7). More recently both central and peripheral
32 biomarkers have been identified as predicting long-term cognitive decline (8-10). However,
33 these risk factors do not provide short-term predictions of AD disease trajectory. The ability to
34 predict the timing of when a patient will become completely dependent on others would be a
35 powerful tool, enabling patients and families to optimize care and, with newer disease-modifying
36 therapeutics, possibly optimize timing of therapeutic interventions.

37
38 The sequence of deficits affecting different cognitive domains in AD commonly starts with an
39 individual’s executive functioning and processing speed (11). Executive functioning defines the
40 higher-level cognitive skills used to control other cognitive abilities (12, 13) while processing
41 speed is the time it takes to execute multi-step information processing in a mental task (14). Both
42 executive functioning and processing speed support other cognitive processes (15, 16) and may
43 serve as a useful cognitive markers for the early trajectory of AD symptoms, being potentially
44 predictive of a more rapid decline (17, 18). Thus, both of these domains may serve as predictors
45 of an inflection point in AD symptoms, when the individual might begin a period of more rapid
46 global cognitive decline, losing function and freedom.

47

48 In current clinical practice, there are no established guidelines or tools for monitoring cognitive
49 function after diagnosis for the sole purpose of predicting decline. We reasoned that given that
50 deficits in executive function and processing speed often precede more severe cognitive deficits,
51 standardized testing of these two domains may hold value in clinical practice. While not
52 specifically developed for older populations, the U.S. National Institutes of Health Toolbox for
53 the Assessment of Neurological and Behavioral Function (NIH toolbox) includes a Cognition
54 Battery (CB) that includes brief, comprehensive tests for these functions (19). This CB contains a
55 Dimensional Change Card Sort (DCCS) test that is a sensitive and reliable measure of executive
56 functioning and cognitive flexibility (20), and a Pattern Comparison Processing Speed Test
57 (PCPS), which can also evaluate attention and concentration (21). These NIH toolbox
58 assessments are easy to administer and offer standardized, non-invasive measures which can be
59 compared across studies (19).

60
61 The aim of this interim analysis of the Gut-brain Alzheimer's disease Inflammation and
62 Neurocognitive Study (GAINS) cohort was to evaluate early cognitive data as potential
63 predictors of AD-associated global cognitive decline as measured by the modified Alzheimer's
64 Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13). ADAS-Cog is a well-
65 established standard for the assessment of cognitive function in patients with AD with moderate
66 to severe disease and is routinely used to help diagnose patients as having MCI, AD, or normal
67 cognition (22) as well as to measure clinically relevant changes (23, 24). The addition of
68 executive functioning and functional ability items to create ADAS-Cog13 (25) from the original
69 11 question set (ADAS-Cog11) has improved the test's sensitivity in milder disease (26), but the
70 test still lacks an assessment of processing speed and skews towards language and verbal

71 memory tasks. While greater changes in ADAS-Cog and ADAS-Cog13 scores over time have
72 been associated with AD versus MCI (27), both tests remain in essence, a measure of cognitive
73 ability at a given point in time.

74

75 We followed participants in the GAINS cohort at 3-month intervals and assessed their NIH
76 toolbox DCCS and PCPS and ADAS-Cog13 scores. In this longitudinal cohort, a 5-point
77 decrease in the cognitive domains of DCCS or PCPS was predictive of global cognitive and
78 functional decline as measured by the ADAS-Cog13.

79 **METHODS**

80 **Study Setting and Population**

81 Older adults, ≥ 60 years of age, living independently, were recruited into the Gut-brain
82 Alzheimer's disease Inflammation and Neurocognitive Study (GAINS) and included those
83 diagnosed with Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), or had no
84 cognitive issues, serving as healthy controls (cHC). Subjects were included in this sub-group
85 analysis if they had completed 4 study visits (270 days). This prospective cohort study was
86 approved by the institutional review board at the University of Massachusetts Chan Medical
87 School.

88

89 **Data Collection**

90 We collected demographic measures at enrollment, which included age, sex, race, ethnicity, level
91 of education, and past medical history. At enrollment and at each subsequent visit, we collected
92 information on nutritional status, frailty, and any hospitalizations or changes in medication. We
93 assessed nutritional status using the Mini Nutritional Assessment (MNA) tool (28-30). Subjects
94 were categorized as normal, at risk, or malnourished based on the MNA. Frailty was categorized
95 according to the validated and widely-utilized Canadian Study of Health and Aging's (CSHA) 7-
96 point Clinical Frailty Scale (31).

97

98 During each visit, cognitive testing was performed. We used the modified Alzheimer's Disease
99 Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13). ADAS-Cog was developed to
100 measure cognitive dysfunction in AD, but is now used for assessment of cognition in other
101 dementia or pre-dementia populations, and is one of the most widely-used cognitive scales in

102 clinical trials (27, 32). We also utilized the NIH toolbox to assess changes in cognition under the
103 subdomains of attention/concentration, using the Pattern Comparison Processing Speed Test
104 (PCPS), and executive functioning using the Dimensional Change Card Sort (DCCS) (33). The
105 Toolbox PCPS provides a reliable measurement of complex processing speed over the lifespan
106 that is sensitive to neurological insults (34).

107
108 For our measure of global cognition, we chose to use the ADAS-Cog13 due to its improved
109 responsiveness as compared with the original ADAS-Cog among people with MCI and early
110 disease course AD, as well as its ability to distinguish different stages of AD (22, 26).
111 Longitudinally, we used a 4-point change in the ADAS-Cog13 score from the day 0 visit as
112 clinically meaningful, either as an improvement (≤ -4 points) or as a decline $\geq +4$ points) (35-
113 37). Those that remained within 4 points of their initial visit ADAS-Cog13 scores were
114 categorized as stable, while those with improvement were categorized as improved, and
115 declining as decline. We chose the first timepoint where a subject had a change in ADAS-Cog13
116 score of ≤ -4 points as the point of decline and the previous visit as the 3 months prior, and the
117 visit before that as 6 months prior to decline. All other previous timepoints were labeled as
118 baseline for analysis.

119
120 Determination of AD diagnosis was made by previous cognitive testing coupled with various
121 neuroimaging techniques performed by the subjects' own physician.
122 Polypharmacy was defined using the most commonly reported definition of five or more daily
123 medications (38). We subdivided our cohort into 4 age categories for analysis: 1) 65 to 74; 2) 75
124 to 84; 3) 85 to 94; and 4) ≥ 95 years of age. This has been previously validated in demonstrating

125 signatures of frailty in the gut microbiota (39-41). All survey data was collected by trained
126 research staff or study physicians. Study data were collected and managed using REDCap
127 electronic data capture tools hosted at the University of Massachusetts Chan Medical School.(42)

128

129 **Data Analysis**

130 We used chi-square tests to compare categorical variables, and the student's independent-
131 samples t-test for continuous variables between patient groups with different outcomes from their
132 baseline data. To test the equality of standard deviations (variance) we used the sdtest package in
133 Stata. Cox proportional hazards models were used to evaluate the NIH neuropsychological
134 measures that predicted time to significant global cognitive decline, as defined by a greater than
135 4-point increase in ADAS-Cog13 testing, as described above. The hazard ratio indicates the
136 change in risk per 5-unit change in the predictor. For instance, if the hazard ratio for PCPS is
137 1.57, each 5-point change in PCPS equates to an increases risk by 57%. Two sets of adjusted
138 Cox models were completed each for PCPS and DCCS, where these neuropsychological
139 measures were adjusted for age (in years), sex, education level, frailty, malnutrition, and
140 polypharmacy. The software used for the analyses was Stata, Release 13.1 (StataCorp LLC,
141 College Station, TX) and Prism Release 10 (GraphPad by Dotmatics, Ltd., United Kingdom).

142

143 **RESULTS**

144 **Clinical and cognitive scores differed among GAINS cohort patient groups**

145 We enrolled 243 older adults, and at the time of this analysis, 183 (75.3%) completed 4 study
146 visits for a longitudinal length of 270 days and were eligible for the analysis. Of these 183 adults
147 in the GAINS cohort, 131 (71.2%) were cHC while 24 (13.0%) had AD and 29 (15.8%) had
148 MCI. This cohort was predominately white (95.1%) and non-Hispanic (91.8%). Unsurprisingly,
149 adults with AD and MCI were older, with higher frailty and malnutrition scores as well as taking
150 more daily medications as defined by polypharmacy (**Table 1**). This is consistent with what is
151 known about frailty and malnutrition in relation to AD and mild cognitive impairment (43-46).
152 Both frail and pre-frail elders usually have poorer cognitive status (47), and frailty has been
153 linked to the extent of AD pathophysiology (44). Malnutrition is also closely linked to decreased
154 cognitive functioning (43). Not surprisingly, mean score on the ADAS-Cog13 increased from
155 cHC, to MCI and AD subjects, and NIH Toolbox module mean scores decreased from cHC, to
156 MCI and AD subjects (**Table 1**). These results further validate the ADAS-Cog13 in
157 responsiveness between cognitively healthy individuals and those with MCI versus AD. They
158 also demonstrate the utility of the NIH toolbox cognitive modules in distinguishing these
159 populations.

160

161

	HC	MCI	AD	p-value
Age *	70.2 (7.6)	75.4 (7.2)	74.3 (5.6)	<0.001
Male	39 (29.8)	15 (51.7)	11 (45.8)	0.042
Education level	6.0 (1.5)	5.8 (1.2)	5.7 (1.7)	0.43
Malnutrition Score*	1.2 (0.5)	1.3 (0.5)	1.8 (0.7)	<0.001
CFS *	2.1 (1.0)	2.6 (1.0)	3.8 (1.4)	<0.001
Polypharmacy	34 (26.0)	10 (34.5)	16 (66.7)	<0.001

BMI	27.7 (6.0)	26.7 (4.9)	26.1 (6.3)	0.44
ADAS-Cog13	8.9 (4.6)	19.4 (9.2)	36.8 (22.5)	<0.001
PCPS	93.5 (14.2)	83.6 (16.4)	66.2 (20.1)	<0.001
DCCS	101.2 (10.0)	96.8 (12.5)	84.0 (18.3)	<0.001
Data presented as n (%) unless marked with * then presented means (sd). CFS – Clinical Frailty Score; BMI – body mass index; ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort				

162

163 **Cognitive Outcomes in AD was not correlated with initial cognitive scores**

164 Among the GAINS cohort we noted 3 cognitive trajectory patterns on longitudinal ADAS-Cog13

165 testing. Using a change in score of +/- 4 in ADAS-Cog testing for 2 or more timepoints to

166 categorize outcomes, 48 patients improved their scores over time (26.1%), 119 patients remained

167 stable (64.7), and 17 patients experienced cognitive decline (9.2%). Of those with AD, 14 had

168 cognitive decline (58.3%) while 8 remained stable (33.3%) and 2 improved (8.3%). Among AD

169 patients, there were no significant differences among the 3 cognitive outcomes observed (**Table**

170 **2**). Importantly, there were no differences in the day 0 cognitive scores using the ADAS-Cog or

171 NIH toolbox among the AD subjects by cognitive trajectory outcome. In the cHC and MCI

172 patient groups, there were a combined n=5 patients with decline (3.1%), who were older and had

173 worse initial ADAS-Cog testing scores (**Supplemental Table 1**).

174

	Improve (2)	Stable (8)	Decline (14)	p-value
Age (years/SD)*	76.0 (4.2)	76.5 (4.3)	72.7 (6.2)	0.30
Male	0 (0.1)	4 (50.0)	7 (50.0)	0.40
Education level*	5.0 (2.8)	6.1 (1.7)	5.6 (1.7)	0.52
Malnutrition Score*	1.5 (0.7)	2.0 (0.9)	1.8 (0.6)	0.64
CFS*	3.0 (1.4)	3.8 (1.8)	3.9 (1.3)	0.71
Polypharmacy	1 (50.0)	6 (75.0)	9 (64.3)	0.77
BMI*	29.8 (4.9)	26.0 (5.8)	25.7 (7.0)	0.70
ADAS-Cog13*	31.3 (25.0)	38.8 (29.9)	38.3 (19.2)	0.92
PCPS *	59.0 (14.1)	74.3 (19.3)	60.7 (19.4)	0.35

DCCS*	79.0 (19.8)	94.2 (16.1)	80.5 (19.3)	0.33
Data presented as n (%) unless marked with * then presented means (sd). CFS – Clinical Frailty Score; BMI – body mass index; ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort				

175

Supplemental Table 1: Characteristics of cHC and MCI patients by cognitive outcomes				
	Improve (45)	Stable (110)	Decline (5)	p-value
Age (years/SD)*	73.1 (6.5)	70.1 (8.0)	75.4 (9.8)	0.042
Male	19 (42.2)	33 (46.0)	2 (40.0)	0.33
Education level*	5.9 (1.6)	6.0 (1.4)	5.6 (2.1)	0.76
Malnutrition Score*	1.2 (0.5)	1.2 (0.5)	1.3 (0.5)	0.98
CFS*	2.3 (0.9)	2.1 (1.1)	2.0 (0.8)	0.73
Polypharmacy	13 (28.9)	29 (26.4)	2 (40.0)	0.78
BMI*	28.0 (6.3)	27.3 (5.7)	27.2 (3.6)	0.82
ADAS-Cog13*	14.0 (5.2)	9.2 (5.9)	22.1 (18.0)	<0.001
PCPS *	87.7 (13.0)	93.4 (15.6)	86.3 (18.4)	0.08
DCCS*	101.1 (6.9)	100.2 (11.8)	96.0 (6.6)	0.64
Data presented as n (%) unless marked with * then presented means (sd). CFS – Clinical Frailty Score; BMI – body mass index; ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort				

176

177 **Significant variance in cognitive testing exists between cognitively healthy older adults and**
 178 **those with MCI and AD**

179 To further characterize the baseline characteristics of our study groups (cHC, MCI, AD), we
 180 examined the variance between individuals (between) as well as within-person variance (within)
 181 (**Table 3**) as standard deviations are not easy to interpret without a frame of reference (48). Both
 182 the between- and within- variance increased from cHC to MCI to AD patients for ADAS-Cog13
 183 testing (**Table 3**). For both the NIH toolbox assessment of PCPS and DCCS, we did not observe
 184 differences in within-group variance across groups. This is reflected in the increasing intraclass
 185 correlation coefficient as one goes from cHC to MCI to AD among all cognitive tests
 186 (**Supplemental Table 2**, all p<0.01). The values in Table 3 indicate that there is considerable
 187 within-person variability in each of the measures of cognitive functioning. Moreover, the within-

188 person to between-person variability ratios were somewhat larger for the cHC patients compared
 189 to those with MCI or AD mostly due to the near doubling of between variance as we move from
 190 HC to MCI to AD across all cognitive testing types. The variance for the cHC and MCI groups
 191 indicate that the variation for a given individual from one test occasion to the next is more than
 192 half as much as the variation from one person to the next. This was the opposite tendency for AD
 193 patients where variation for the individual was one quarter to one third of the variation from one
 194 person to the next across cognitive tests.

Table 3: Variance among different cognitive group types			
	HC	MCI	AD
ADAS-Cog13			
Mean (SD)	7.5 (4.5)	17.0 (10.4)	37.8 (23.3)
Between variance	3.9	10.7	23.4
Within variance	2.5	3.1	5.7
Within/Between	0.64	0.29	0.24
PCPS			
Mean (SD)	99.6 (14.8)	89.9 (17.8)	70.6 (20.5)
Between variance	12.5	16.7	21.4
Within variance	8.1	8.0	8.1
Within/Between	0.65	0.50	0.38
DCCS			
Mean (SD)	103.0 (8.8)	99.7 (10.8)	87.7 (17.1)
Between variance	7.2	10.1	19.4
Within variance	5.3	5.5	6.1
Within/Between	0.74	0.54	0.31
P-value	< 0.01	< 0.01	< 0.01
HC – Healthy Control; MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; ADAS-Cog13 - Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13; PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort			

195
 196
 197

Supplemental Table 2: Intraclass correlation coefficients among different cognitive group types

	HC		MCI		AD	
ADAS-Cog13	0.63	(0.56-0.70)	0.90	(0.84-0.95)	0.93	(0.89-0.98)
PCPS	0.65	(0.58-0.72)	0.76	(0.65-0.88)	0.82	(0.71-0.93)
DCCS	0.56	(0.48-0.64)	0.69	(0.55-0.84)	0.86	(0.76-0.95)
Data presented as means (95% confidence intervals). HC – Healthy Control; MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort						

198

199

200 **NIH Toolbox assessments of executive functioning decline as early as 6 months prior to**
201 **cognitive decline measured by ADAS-Cog13**

202 In light of the differences in variances between tests among patients, we next sought to determine
203 whether longitudinal patterns between cognitive outcomes (declined, stable, improved) were
204 correlated with cognitive testing trends. Among the AD patients within the GAINS cohort, we
205 first explored differences between those who experienced a decline in cognition versus those
206 who did not (both stable and improved patients). We did not observe any differences in
207 demographic or clinical characteristics, including in the medications taken by the subjects during
208 the study period (**Supplemental Table 3**). We did, however, notice a significant decline in
209 executive functioning testing, in both NIH toolbox PCPS and DCCS, at the 3- and 6-month visits
210 before a decline in cognition measured by the ADAS-Cog13 compared to all other timepoints
211 where the ADAS-Cog13 testing was stable (**Figure 1a**). There were no significant differences in
212 ADAS-Cog13 testing scores at these same time points. The differences from baseline score tests
213 are visualized in **Figure 1b**.


214

Supplemental Table 3: Clinical Characteristics between Alzheimer's disease patients with and without cognitive decline			
	Stable (10)	Decline (14)	p-value
Age (years/SD)*	76.4 (4.0)	72.7 (6.2)	0.12
Male	4 (40.0)	7 (50.0)	0.63
Education level*	5.9 (1.9)	5.6 (1.7)	0.38
Malnutrition Score*	1.9 (0.9)	1.8 (0.6)	0.59
CFS*	3.6 (1.7)	3.9 (1.3)	0.59
Polypharmacy	7 (70.0)	9 (64.3)	0.77
BMI*	26.8 (5.6)	25.7 (7.0)	0.70
Data presented as n (%) unless marked with * then presented means (sd). CFS - Clinical Frailty Score; BMI - body mass index			

215

216

217



218

219

220 We next performed univariate cox models predicting cognitive decline by ADAS-Cog for both
221 NIH toolbox domains for PCPS and DCCS among AD patients. We used a 5-point decline in
222 both NIH CB tests as predictor of general cognitive decline given the mean change at both 3 and
223 6 months prior in each test was about 5 points. Both in the crude and adjusted models, a 5-point
224 change in PCPS or DCCS was associated with a 24% to 32% or 44% to 62% increased risk of
225 cognitive decline respectively (**Table 4**). In the modeling, adjustments were made for age, sex,
226 education, frailty, malnutrition and polypharmacy.

227

Table 4: Analysis of NIH Toolbox Cognitive Testing and Risk of Cognitive Decline				
	Crude		Adjusted †	
	Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value
PCPS delta	1.24 (1.08-1.43)	0.002	1.32 (1.08-1.60)	0.006
DCCS delta	1.44 (1.16-1.77)	0.001	1.62 (1.16-2.26)	0.005

PCPS – NIH Toolbox Pattern Comparison Processing Speed Test; DCCS - NIH Toolbox Dimensional Change Card Sort; delta is for every 5-point decrease in score
† Adjusted for age, sex, education, frailty, malnutrition, and polypharmacy

228

229

230 **DISCUSSION**

231 In this study we found that as early as 6 months prior to a global cognitive decline, there were
232 significant decreases in processing speed and executive functioning among AD patients using the
233 NIH toolbox CB assessments for PCPS and DCCS. There was also a noted increase in the
234 between-person variability from cHC to MIC to AD subjects using either the ADAS-Cog or NIH
235 toolbox modules, however the within-group variability only increased between these groups in
236 the ADAS-Cog assessments, with the greatest variability in among AD patients. A 5-point
237 decrease in either PCPS and DCCS resulted in a greater than 30% increased risk of subsequent
238 global cognitive decline. We propose here that these NIH toolbox assessments for executive
239 functioning and processing speed may serve as a monitoring tool to predict which AD patients
240 will go on to experience clinically significant cognitive decline.

241

242

243 Executive function comprises the higher-level cognitive skills used to control and
244 coordinate other cognitive abilities and behaviors (12, 13). Deficits in executive functioning have
245 been shown as one of the most useful cognitive markers for the early detection of AD (17), and
246 declining performance can be detected 2-3 years before the diagnosis of AD (49). Executive
247 dysfunction occurs in all stages of AD and has been linked to functional decline in activities of
248 daily living (50, 51). Executive functioning is also one of the cognitive domains in AD that
249 shows the greatest decline and can indicate a faster disease progression (52-54). The ADAS-Cog
250 test does a poor job of testing for executive functioning. It was built based on the original
251 ADAS-Cog (55), and the ADAS-Cog13 or ADAS-Cog-Modified had delayed word recall or
252 number cancellation added in order to improve the tests responsiveness, to cover the range of
253 mild to moderate AD (25). Others tried adding additional testing domains to the ADAS-Cog test
254 to better cover executive functioning testing such as the ADAS-Cog-Exec (56) and ADAS-Cog-
255 Plus (26). These additional testing modules are not universally used, with the ADAS-Cog still
256 considered the gold standard (27) especially for assessing efficacy of AD treatments.

257
258 As we age, both executive functioning and processing speed decline, and this decline is linked to
259 performance in learning and memory (57). The processing speed theory states that the age-
260 related decline in processing speed is the fundamental mechanism with which memory declines
261 with normal aging (58). However, executive functions and processing speed can differentially
262 influence memory decline (57). Processing speed is thought to serve as the foundation for other
263 cognitive processes (15) and it is associated with subsequent deficits in other cognitive domains
264 such as working memory (59), attention (60) and memory (61). Disproportionate slowing of
265 processing speed has been shown to be related to a faster decline in AD (18). Our finding is

266 consistent with a predictive role of processing speed change: the NIH toolbox CB Comparison
267 Processing Speed Test to assess processing speed in GAINS participants was sensitive to early
268 cognitive change, with decreases in processing speed preceding global cognitive decline, with a
269 5 point drop in score increasing the risk of cognitive decline by greater than 30%, after
270 adjustment.

271
272 Instead of expanding the ADAS-Cog to improve its sensitivity, it might be of greater benefit to
273 predict cognitive decline by periodically test executive functioning with other standard measures.
274 The NIH toolbox CB is a set of brief measures assessing cognitive domains including executive
275 functioning studies (19). Subjects that are part of a clinical trial could self-administer these tests
276 as an alternative to the ADAS-Cog, which takes upwards of 45 minutes to administer and needs
277 to be done in-person by trained staff (27). Remote digital cognitive testing is now being shown to
278 be an accurate method to detect cognitive impairment (62-64). A robust tool with a 3 to 6-month
279 predictive window would offer patients and families a reasonable timeframe to make practical
280 care arrangements such as changing living situation, finding caretakers, or applying for elder
281 care benefits and services.

282
283 This study does have limitations. First, the majority of the GAINS cohort was without AD,
284 which influences the within-group variance in the AD group. Testing NIH toolbox assessments
285 for their ability to predict cognitive decline in a larger longitudinal cohort would strengthen the
286 findings. Additionally, the GAINS cohort was mostly white and non-Hispanic, limiting the
287 generalizability of our data. These limitations are balanced by the frequent in-person model to
288 assess both ADAS-Cog and the NIH toolbox CB domains.

289 **Conclusion**

290 Based on our findings, we would suggest that brief assessments of both executive functioning
291 and processing speed may serve as a marker of subsequent global cognitive decline. This can be
292 helpful clinically for planning the timing of treatments, interventions, or life management,
293 especially if executive function and processing speed testing is potentially more rapid than a
294 comprehensive cognitive testing session, and more feasibly performed frequently. Tools such as
295 PCPS and DCCS could also help researchers as well as clinicians with monitoring efficacy of
296 AD treatments as part of clinical trials of disease-modifying therapy.

297

298 **AUTHOR CONTRIBUTIONS**

299 JPH (Data curation; Conceptualization; Formal analysis; Investigation; Project administration;
300 Funding acquisition; Writing – original draft); AMB (Methodology; Writing – review & editing);
301 SNO (Supervision; Data curation; Writing – review & editing); PD (Supervision; Data curation;
302 Writing – review & editing); PMM (Data acquisition; Data curation; Writing – review &
303 editing); IS (Data acquisition; Writing – review & editing); LR (Data acquisition; Writing –
304 review & editing); YSL (Resources; Writing – review & editing); VB (Conceptualization;
305 Formal analysis; Methodology; Writing – review & editing); BAM (Conceptualization; Writing
306 – review & editing).

307

308 **ACKNOWLEDEMENTS**

309 We would like to thank the administration and staff from the Clinical Research Center here at
310 UMass Medical Center and the Center for Clinical and Translational Sciences at UMass Chan
311 Medical School for clinical facilities that supported the GAINS cohort.

312

313 **FUNDING**

314 This study was designed and carried out at the University of Massachusetts Chan Medical
315 School. JPH was supported by an Alzheimer’s Association Grant (2019-AARG-NTF-641955)
316 and NIH grants from the National Institute on Aging (grant numbers: 2019-AARG-NTF-641955,
317 R01AG067483-01). This prospective cohort study was approved by the institutional review
318 board at the University of Massachusetts Chan Medical School (IRB docket H00021745).

319

320 **CONFLICT OF INTEREST**

321 The authors have no conflict of interest to report.

322

323 **DATA AVAILABILITY**

324 The data supporting the findings of this study are available on request from the corresponding
325 author. The data are not publicly available due to privacy or ethical restrictions.

326

327 **REFERENCES**

- 328 1. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. 2021. Population
329 estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the
330 United States (2020-2060). *Alzheimers Dement* 17:1966-1975.
- 331 2. Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk
332 WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C. 2021. Predicting
333 Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. *Neurology*
334 97:e1823-e1834.
- 335 3. Kosciak RL, Betthausen TJ, Jonaitis EM, Allison SL, Clark LR, Hermann BP, Cody KA,
336 Engle JW, Barnhart TE, Stone CK, Chin NA, Carlsson CM, Asthana S, Christian BT,
337 Johnson SC. 2020. Amyloid duration is associated with preclinical cognitive decline and
338 tau PET. *Alzheimers Dement (Amst)* 12:e12007.
- 339 4. Insel PS, Donohue MC, Berron D, Hansson O, Mattsson-Carlgren N. 2021. Time
340 between milestone events in the Alzheimer's disease amyloid cascade. *Neuroimage*
341 227:117676.
- 342 5. Xie J, Brayne C, Matthews FE. 2008. Survival times in people with dementia: analysis
343 from population based cohort study with 14 year follow-up. *Bmj* 336:258-62.
- 344 6. Adak S, Illouz K, Gorman W, Tandon R, Zimmerman EA, Guariglia R, Moore MM,
345 Kaye JA. 2004. Predicting the rate of cognitive decline in aging and early Alzheimer
346 disease. *Neurology* 63:108-14.
- 347 7. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, Blacker D,
348 Stern Y. 2008. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer
349 disease. *Neurology* 70:1842-9.

- 350 8. Steenland K, Zhao L, Goldstein F, Cellar J, Lah J. 2014. Biomarkers for predicting
351 cognitive decline in those with normal cognition. *J Alzheimers Dis* 40:587-94.
- 352 9. Gunes S, Aizawa Y, Sugashi T, Sugimoto M, Rodrigues PP. 2022. Biomarkers for
353 Alzheimer's Disease in the Current State: A Narrative Review. *Int J Mol Sci* 23.
- 354 10. Wang H, Sun M, Li W, Liu X, Zhu M, Qin H. 2023. Biomarkers associated with the
355 pathogenesis of Alzheimer's disease. *Front Cell Neurosci* 17:1279046.
- 356 11. Hennekes C, Reed C, Chen YF, Dell'Agnello G, Lebec J. 2016. Describing the Sequence
357 of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational
358 Study. *J Alzheimers Dis* 52:1065-80.
- 359 12. Memory. Aging Center and Aging Center, UCSF Weill Institute for Neurosciences.
360 Executive functions. Available at: <https://memory.ucsf.edu/symptoms/executive->
361 [functions](https://memory.ucsf.edu/symptoms/executive-). Accessed June 6, 2024.
- 362 13. Guarino A, Favieri F, Boncompagni I, Agostini F, Cantone M, Casagrande M. 2018.
363 Executive Functions in Alzheimer Disease: A Systematic Review. *Front Aging Neurosci*
364 10:437.
- 365 14. Ebaid D, Crewther SG, MacCalman K, Brown A, Crewther DP. 2017. Cognitive
366 Processing Speed across the Lifespan: Beyond the Influence of Motor Speed. *Front*
367 *Aging Neurosci* 9:62.
- 368 15. Sliwinski M, Buschke H. 1999. Cross-sectional and longitudinal relationships among age,
369 cognition, and processing speed. *Psychol Aging* 14:18-33.
- 370 16. Rabinovici GD, Stephens ML, Possin KL. 2015. Executive dysfunction. *Continuum*
371 (Minneapolis Minn) 21:646-59.

- 372 17. Crowell TA, Luis CA, Vanderploeg RD, Schinka JA, Mullan M. 2002. Memory Patterns
373 and Executive Functioning in Mild Cognitive Impairment and Alzheimer's Disease.
374 *Aging, Neuropsychology, and Cognition* 9:288-297.
- 375 18. Parikh M, Hynan LS, Weiner MF, Lacritz L, Ringe W, Cullum CM. 2014. Single
376 neuropsychological test scores associated with rate of cognitive decline in early
377 Alzheimer disease. *Clin Neuropsychol* 28:926-40.
- 378 19. Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Slotkin J, Carlozzi NE,
379 Bauer PJ, Wallner-Allen K, Fox N, Havlik R, Beaumont JL, Mungas D, Manly JJ, Moy
380 C, Conway K, Edwards E, Nowinski CJ, Gershon R. 2014. The cognition battery of the
381 NIH toolbox for assessment of neurological and behavioral function: validation in an
382 adult sample. *J Int Neuropsychol Soc* 20:567-78.
- 383 20. Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Conway KP,
384 Gershon R, Weintraub S. 2014. NIH Toolbox Cognition Battery (CB): validation of
385 executive function measures in adults. *J Int Neuropsychol Soc* 20:620-9.
- 386 21. Carlozzi NE, Beaumont JL, Tulsky DS, Gershon RC. 2015. The NIH Toolbox Pattern
387 Comparison Processing Speed Test: Normative Data. *Archives of Clinical*
388 *Neuropsychology* 30:359-368.
- 389 22. Warren SL, Reid E, Whitfield P, Helal AM, Abo Hamza EG, Tindle R, Moustafa AA,
390 Hamid MS. 2024. Cognitive and behavioral abnormalities in individuals with
391 Alzheimer's disease, mild cognitive impairment, and subjective memory complaints.
392 *Current Psychology* 43:800-810.
- 393 23. Schrag A, Schott JM. 2012. What is the clinically relevant change on the ADAS-Cog? *J*
394 *Neurol Neurosurg Psychiatry* 83:171-3.

- 395 24. Karcher H, Savelieva M, Qi L, Hummel N, Caputo A, Risson V, Capkun G, Alzheimer's
396 Disease Neuroimaging I. 2020. Modelling Decline in Cognition to Decline in Function in
397 Alzheimer's Disease. *Curr Alzheimer Res* 17:635-657.
- 398 25. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M,
399 Bieliauskas L, Geldmacher D, Clark C, Thal LJ. 1997. Development of cognitive
400 instruments for use in clinical trials of antimentia drugs: additions to the Alzheimer's
401 Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative
402 Study. *Alzheimer Dis Assoc Disord* 11 Suppl 2:S13-21.
- 403 26. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE. 2012.
404 The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an
405 expansion of the ADAS-Cog to improve responsiveness in MCI. *Brain Imaging Behav*
406 6:489-501.
- 407 27. Kueper JK, Speechley M, Montero-Odasso M. 2018. The Alzheimer's Disease
408 Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness
409 in Pre-Dementia Populations. A Narrative Review. *J Alzheimers Dis* 63:423-444.
- 410 28. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Bruno Vellas B. 2001. Screening for
411 Undernutrition in Geriatric Practice: Developing the Short-Form Mini-Nutritional
412 Assessment (MNA-SF). *J Gerontol A Biol Sci Med Sci* 56A:M366-72.
- 413 29. Saarela RK, Lindroos E, Soini H, Hiltunen K, Muurinen S, Suominen MH, Pitkala KH.
414 2016. Dentition, nutritional status and adequacy of dietary intake among older residents
415 in assisted living facilities. *Gerodontology* doi:10.1111/ger.12144.
- 416 30. Guigoz Y. 2006. The Mini Nutritional Assessment (MNA) review of the literature--What
417 does it tell us? *J Nutr Health Aging* 10:485-7.

- 418 31. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A.
419 2005. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 173:489-
420 95.
- 421 32. Connor DJ, Sabbagh MN. 2008. Administration and scoring variance on the ADAS-Cog.
422 *J Alzheimers Dis* 15:461-4.
- 423 33. Gershon RC, Wagster MV, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. 2013. NIH
424 Toolbox for Assessment of Neurological and Behavioral Function. *Neurology* 80:S2-6.
- 425 34. Anonymous. NIH Toolbox Cognitive Battery (NIHTB-CB): The NIHTB Pattern
426 Comparison Processing Speed Test. doi:10.1017/S1355617714000319.
- 427 35. Matthews HP, Korbey J, Wilkinson DG, Rowden J. 2000. Donepezil in Alzheimer's
428 disease: eighteen month results from Southampton Memory Clinic. *Int J Geriatr*
429 *Psychiatry* 15:713-20.
- 430 36. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S,
431 Thomas RG, Thal LJ. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer
432 disease progression: a randomized controlled trial. *Jama* 289:2819-26.
- 433 37. Le Bars PL, Kieser M, Itil KZ. 2000. A 26-week analysis of a double-blind, placebo-
434 controlled trial of the ginkgo biloba extract EGb 761 in dementia. *Dement Geriatr Cogn*
435 *Disord* 11:230-7.
- 436 38. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. 2017. What is polypharmacy? A
437 systematic review of definitions. *BMC Geriatr* 17:230.
- 438 39. Jackson MA, Jeffery IB, Beaumont M, Bell JT, Clark AG, Ley RE, O'Toole PW, Spector
439 TD, Steves CJ. 2016. Signatures of early frailty in the gut microbiota. *Genome Med* 8:8.

- 440 40. Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, Turrone F,
441 Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Lauretani F, De Vos W,
442 van Sinderen D, Meschi T, Ventura M. 2016. Gut microbiota composition and
443 *Clostridium difficile* infection in hospitalized elderly individuals: a metagenomic study.
444 *Sci Rep* 6:25945.
- 445 41. Haran JP, Bucci V, Dutta P, Ward D, McCormick B. 2018. The nursing home elder
446 microbiome stability and associations with age, frailty, nutrition, and physical location. *J*
447 *Med Microbiol* 67:40-51.
- 448 42. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009, Apr. Research
449 electronic data capture (REDCap) - A metadata-driven methodology and workflow
450 process for providing translational research informatics support. *J Biomed* 42:377-81.
- 451 43. Guerin O, Soto ME, Brocker P, Robert PH, Benoit M, Vellas B, Group. RF. 2005.
452 Nutritional status assessment during Alzheimer's disease: results after one year (the
453 REAL French Study Group). *J Nutr Health Aging* 9:81-4.
- 454 44. Buchman AS, Schneider JA, Leurgans S, Bennett DA. 2008. Physical frailty in older
455 persons is associated with Alzheimer disease pathology. *Neurology* 71:499-504.
- 456 45. Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA. 2007. Frailty is associated
457 with incident Alzheimer's disease and cognitive decline in the elderly. *Psychosom Med*
458 69:483-9.
- 459 46. Meijers JM, Schols JM, Halfens RJ. 2014. Malnutrition in care home residents with
460 dementia. *J Nutr Health Aging* 18:595-600.
- 461 47. Boulos C, Salameh P, Barberger-Gateau P. 2016. Malnutrition and frailty in community
462 dwelling older adults living in a rural setting. *Clin Nutr* 35:138-43.

- 463 48. Salthouse TA. 2007. Implications of within-person variability in cognitive and
464 neuropsychological functioning for the interpretation of change. *Neuropsychology*
465 21:401-11.
- 466 49. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. 2008. Memory
467 impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's
468 disease. *J Int Neuropsychol Soc* 14:266-78.
- 469 50. Tekin S, Fairbanks LA, O'Connor S, Rosenberg S, Cummings JL. 2001. Activities of
470 daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness
471 influences. *Am J Geriatr Psychiatry* 9:81-6.
- 472 51. Skurla E, Rogers JC, Sunderland T. 1988. Direct assessment of activities of daily living
473 in Alzheimer's disease. A controlled study. *J Am Geriatr Soc* 36:97-103.
- 474 52. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. 2001. Patterns of
475 cognitive decline in presymptomatic Alzheimer disease: a prospective community study.
476 *Arch Gen Psychiatry* 58:853-8.
- 477 53. Tosto G, Gasparini M, Brickman AM, Letteri F, Renie R, Piscopo P, Talarico G,
478 Canevelli M, Confaloni A, Bruno G. 2015. Neuropsychological predictors of rapidly
479 progressive Alzheimer's disease. *Acta Neurol Scand* 132:417-22.
- 480 54. Zhao Q, Zhou B, Ding D, Teramukai S, Guo Q, Fukushima M, Hong Z. 2014. Cognitive
481 decline in patients with Alzheimer's disease and its related factors in a memory clinic
482 setting, Shanghai, China. *PLoS One* 9:e95755.
- 483 55. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. *Am J*
484 *Psychiatry* 141:1356-64.

- 485 56. Jacobs DM, Thomas RG, Salmon DP, Jin S, Feldman HH, Cotman CW, Baker LD. 2020.
486 Development of a novel cognitive composite outcome to assess therapeutic effects of
487 exercise in the EXERT trial for adults with MCI: The ADAS-Cog-Exec. *Alzheimers*
488 *Dement (N Y)* 6:e12059.
- 489 57. Saikia B, Tripathi R. 2024. Executive Functions, Processing Speed, and Memory
490 Performance: Untangling the Age-related Effects. *Journal of Psychiatry Spectrum* 3:12-
491 19.
- 492 58. Salthouse TA. 1996. The processing-speed theory of adult age differences in cognition.
493 *Psychol Rev* 103:403-28.
- 494 59. Chiaravalloti ND, Christodoulou C, Demaree HA, DeLuca J. 2003. Differentiating
495 simple versus complex processing speed: influence on new learning and memory
496 performance. *J Clin Exp Neuropsychol* 25:489-501.
- 497 60. Mayes SD, Calhoun SL. 2007. Learning, attention, writing, and processing speed in
498 typical children and children with ADHD, autism, anxiety, depression, and oppositional-
499 defiant disorder. *Child Neuropsychol* 13:469-93.
- 500 61. Baudouin A, Clarys D, Vanneste S, Isingrini M. 2009. Executive functioning and
501 processing speed in age-related differences in memory: contribution of a coding task.
502 *Brain Cogn* 71:240-5.
- 503 62. Berron D, Olsson E, Andersson F, Janelidze S, Tideman P, Düzel E, Palmqvist S,
504 Stomrud E, Hansson O. 2024. Remote and unsupervised digital memory assessments can
505 reliably detect cognitive impairment in Alzheimer's disease. *Alzheimers Dement*
506 20:4775-4791.

- 507 63. Boots EA, Frank RD, Fan WZ, Christianson TJ, Kremers WK, Stricker JL, Machulda
508 MM, Fields JA, Hassenstab J, Graff-Radford J, Vemuri P, Jack CR, Knopman DS,
509 Petersen RC, Stricker NH. 2024. Continuous Associations between Remote Self-
510 Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease. The
511 Journal of Prevention of Alzheimer's Disease doi:10.14283/jpad.2024.99.
- 512 64. Butler J, Watermeyer TJ, Matterson E, Harper EG, Parra-Rodriguez M. 2024. The
513 development and validation of a digital biomarker for remote assessment of Alzheimer's
514 diseases risk. DIGITAL HEALTH 10:20552076241228416.
- 515